Medically reviewed by Qin Rao, MD Metabolic dysfunction-associated steatohepatitis (MASH), previously known as non-alcoholic steatohepatitis (NASH), is a type of liver disease where fat build-up in ...

Sagimet Biosciences (NASDAQ:SGMT) traded higher on Thursday after Canaccord Genuity launched its coverage with a Buy recommendation, citing the potential of its lead asset denifanstat, targeted at a ...

Fat accumulation in the liver, common in both non-drinkers (NAFLD, now MASLD) and those who consume alcohol (AFLD), may ...

UAB researchers have reversed metabolic dysfunction-associated steatohepatitis (MASH) in mouse models. MASH is a severe liver disease associated with obesity and type 2 diabetes that affects more ...

Altimmune's pemvidutide showed strong MASH resolution and good tolerability in IMPACT, but fibrosis data fell short. See why ...

Metabolic dysfunction-associated steatohepatitis (MASH) represents a serious form of fatty liver disease that can lead to permanent damage while producing few noticeable symptoms.

With the FDA due to approve Madrigal's MASH drug, Ionis is raising its hand to showcase a phase 2 asset that has improved symptoms of the disease.

Metabolic dysfunction- associated steatohepatitis, or MASH, is an inflammatory, liver-scarring disease that has reached epidemic proportions, with an estimated 1.5% to 6.5% of U.S. adults ...

In a placebo-controlled, 24-week Phase 2 test that enrolled 84 MASH patients in stages 2 or 3 of the disease (stage 4 is liver cirrhosis), Boston Pharma reported results showing statistically ...

Madrigal’s stock surges as FDA approves first drug for liver disease MASH ‘Silent’ disease affects an estimated 5% of U.S. adults Last Updated: March 15, 2024 at 8:31 a.m. ET First Published ...